A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

被引：3
|
作者：
Lakhani, Nehal J.
Rasco, Drew W.
Tolcher, Anthony W.
Huang, Yingjie
Ji, Jiao
Wang, Hengbang
Dong, Qi
Men, Lichuang
O'Rourke, Timothy J.
Chandana, Sreenivasa R.
Amaya, Alex
Cole, Yvette
Kaiser, Brianne
Mays, Theresa A.
Patnaik, Amita
Papadopoulos, Kyriakos P.
Yang, Dajun
Zhai, Yifan
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[3] Ascentage Pharma Grp Inc, Rockville, MD USA
[4] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[5] Suzhou Ascentage Pharma Inc, Suzhou, Peoples R China
[6] Canc & Hem Ctr West Michigan, Grand Rapids, MI USA
[7] Western Michigan Canc Ctr, Kalamazoo, MI USA
[8] START Ctr Canc Care, San Antonio, TX USA
[9] START Midwest Canc Hematol Centers Western Michig, Grand Rapids, MI USA
[10] South Texas Accelerated Res Therapeut START Ctr C, San Antonio, TX USA
[11] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2594
引用
收藏
页数：1
相关论文
共 50 条
  • [31] AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models
    Balachander, Srividya B.
    Tabatabai, Areya
    Wen, Shenghua
    Gibbons, Francis D.
    Fabbri, Giulia
    Zhang, Guangnong Sunny
    Cidado, Justin
    Graham, Lorraine
    Ashford, Marianne
    Davies, Barry
    CANCER RESEARCH, 2020, 80 (16)
  • [32] Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer
    Lu, Yingjie
    Bian, Dongliang
    Zhang, Xuelin
    Zhang, Huibiao
    Zhu, Zhenghong
    MOLECULAR MEDICINE REPORTS, 2021, 23 (01) : 1 - 9
  • [33] AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
    Balachander, Srividya B.
    Criscione, Steven W.
    Byth, Kate F.
    Cidado, Justin
    Adam, Ammar
    Lewis, Paula
    Macintyre, Terry
    Wen, Shenghua
    Lawson, Deborah
    Burke, Kathleen
    Lubinski, Tristan
    Tyner, Jeffrey W.
    Kurtz, Stephen E.
    McWeeney, Shannon K.
    Varnes, Jeffrey
    Diebold, R. Bruce
    Gero, Thomas
    Ioannidis, Stephanos
    Hennessy, Edward J.
    McCoull, William
    Saeh, Jamal C.
    Tabatabai, Areya
    Tavana, Omid
    Su, Nancy
    Schuller, Alwin
    Garnett, Mathew J.
    Jaaks, Patricia
    Coker, Elizabeth A.
    Gregory, Gareth P.
    Newbold, Andrea
    Johnstone, Ricky W.
    Gangl, Eric
    Wild, Martin
    Zinda, Michael
    Secrist, J. Paul
    Davies, Barry R.
    Fawell, Stephen E.
    Gibbons, Francis D.
    CLINICAL CANCER RESEARCH, 2020, 26 (24) : 6535 - 6549
  • [34] Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study
    de Vos, Sven
    Leonard, John P.
    Friedberg, Jonathan W.
    Zain, Jasmine
    Dunleavy, Kieron
    Humerickhouse, Rod
    Hayslip, John
    Pesko, John
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 810 - 818
  • [35] Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).
    Qin, Angel
    Kalemkerian, Gregory Peter
    Patel, Jyoti D.
    Mohindra, Nisha Anjali
    Carlisle, Jennifer W.
    Sands, Jacob
    He, Zhicong
    Winkler, Robert
    Liang, Zhiyan
    Hammock, Vakessa
    Bombelli, Riccardo
    Lu, Ming
    Xu, Yang
    Fu, Tommy
    Wang, Cunlin
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
    Qin, Angel
    Kalemkerian, Gregory Peter
    Mohindra, Nisha Anjali
    Patel, Jyoti D.
    Karapetis, Christos Stelios
    Carlisle, Jennifer W.
    Sands, Jacob
    Spira, Alexander I.
    Gao, Bo
    Amin, Harshad
    Paudyal, Bishnuhari
    Frank, Genevieve
    Sun, Xuemei
    Xu, Yang
    Wang, Cunlin
    Fu, Tommy
    Winkler, Robert
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Bcl-2 and Bcl-xL dual inhibitor, ABT-737, circumvents JNK mediated upregulation of anti-apoptotic molecules in cisplatin treated non-small cell lung cancer models
    Kim, Eun Young
    Kim, Arum
    Chang, Yoon Soo
    CANCER RESEARCH, 2015, 75
  • [38] AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models
    Andersen, Courtney L.
    Fabbri, Giulia
    Jenkins, David
    Cader, Zumla
    Sharma, Shringi
    Tabatabai, Areya
    Balachander, Srividya
    Roebuck, Jordan
    Galvin, Melanie
    Simpson, Kathryn
    Dive, Caroline
    Ahnert, Jordi Rodon
    Saeh, Jamal
    CANCER RESEARCH, 2023, 83 (07)
  • [39] Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment
    Messaritakis, Ippokratis
    Nikolaou, Michail
    Politaki, Eleni
    Koinis, Fillipos
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Georgoulia, Nefeli
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    LUNG CANCER, 2018, 124 : 270 - 278
  • [40] Radiation enhances the efficacy of Bcl-2 and Bcl-XL inhibition in small cell lung cancer: A new concept of using radiation for targeted therapy through contextual oncogene addiction
    Loriot, Yohann
    Mordant, Pierre
    Dugue, Delphine
    Gombos, Andrea
    Opolon, Paule
    Vozenin, Marie-Catherine
    Bourhis, Jean
    Geneste, Olivier
    Kraus-Berthier, Laurence
    Pierre, Alain
    Depil, Stephane
    Soria, Jean-Charles
    Deutsch, Eric
    CANCER RESEARCH, 2012, 72
12345